Review
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2006; 12(21): 3306-3313
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3306
Table 2 Antibiotics trials in active Crohn’s disease
StudyPatients (n)wkMain outcomeStudy designTreatment schedules
Blichfeldt et al[28]228Improvement (clinical/lab score)DB crossover studyMZ (+ SASP/CS) Placebo (+ SASP/CS)
Ursing et al[29]2216Change in CDAI and orosomucoidDB crossover studyMZ SASP
Ambrose et al[30]724Improvement (Clinical/lab.score)DB RCTMZ CO, MZ/CO, placebo
Sutherland et al[31]9916Change in CDAI from baselineDR RCTMZ (10/20 mg/kg) Placebo
Prantera et al[32]4112Clinical remission (CDAI < 150)NB RCTMZ + Cipro Steroids
Colombel et al[34]406Clinical remission (CDAI < 150)NB RCTCIPRO 5-ASA
Arnold et al[35]4724Change in CDAINB RCTCIPRO (+ conc drugs) Placebo (+ conc drugs)
Steinhart et al[33]1348Clinical remission (CDAI < 150)DB RCTMZ+CIPRO (+ bud 9 mg) Placebo (+ bud. 9 mg)